U lcerative colitis (UC) is a relapsing chronic disease. 1 Although the extent of mucosal inflammation varies widely from proctitis to extensive colitis, up to 30% to 60% of these patients suffer from limited distal disease. 2 Although the extent of inflammation in proctitis is the least among all forms of UC, its contribution to symptoms and quality of life is particularly pronounced. 3 Topical therapy with mesalamine or budesonide is the mainstay in left-sided or distal UC, with mesalamine being the gold standard for mild to moderately active UC. 4, 5 When given orally, active compound inevitably is lost via absorption in the intestines' proximal parts, leading to unwanted systemic reactions and low drug concentrations at the site of colonic inflammation. Rectal therapy circumvents these drawbacks of oral treatment because local concentrations of the active drug are high, while systemic absorption is low owing to the biotransformation of mesalamine to a pharmacologically inactive metabolite already in the intestinal mucosa. 6 Consequently, rectal administration of mesalamine, and in particular mesalamine suppositories, are recommended as first-line treatment for mild to moderately active ulcerative proctitis. 5, [7] [8] [9] [10] Although the efficacy and safety of mesalamine suppositories for acute proctitis is well documented, 4 there are no reliable clinical data available for the rectal administration of budesonide with suppositories. To this end, we developed budesonide suppositories that combine the preferred mode of drug delivery for proctitis together with budesonide's favorable safety profile. Two different doses of budesonide were evaluated vs standard treatment with mesalamine suppositories. In addition, we also analyzed the efficacy of combined therapy with budesonide and mesalamine suppositories.
Materials and Methods

Study Design
This was a double-blind, double-dummy, randomized (1:1:1:1), multicenter, active-controlled, 8-week, exploratory phase 2 clinical trial in patients suffering from mild to moderately active ulcerative proctitis. This study was conducted with 4 treatment groups in the form of a parallel group comparison. Because the trial was exploratory, we did not perform a formal sample size calculation and no type I error or power was defined. The sample size was set to 80 patients per treatment group, thus we planned to randomize 320 patients. This study used a double-dummy technique to maintain and ensure blinding. The trial period for an individual patient consisted of a 56-day treatment period with 5 scheduled trial visits. The study took place from November 2013 until July 2015 with 15 active sites in Germany, 12 in Russia, and 9 in Ukraine. The study was conducted in accordance with good clinical practice, the Declaration of Helsinki, and all applicable national laws, and was approved by independent ethics committees at each of the centers before starting the study.
Patients
Men and women aged 18 to 75 years old with established or newly diagnosed mildly to moderately active ulcerative proctitis (maximum, 15 cm from the anal margin; modified version of the standard Ulcerative Colitis Disease Activity Index [mUC-DAI] 11-13 4-10 with an endoscopic subscore of 1) (Supplementary Table 1) confirmed by endoscopy and negative stool cultures were included. Exclusion criteria are shown in the Supplementary Methods section. All patients provided written informed consent before participating in this study.
Procedures
Efficacy and safety assessments were conducted at baseline, at the 3 interim visits every 2 weeks, and at the final visit in week 8. Endoscopy was performed at baseline and at the final visit in week 8. In addition, patients had to keep diaries for further assessment of efficacy, tolerability, and safety. Detailed study procedures are shown in the Supplementary Methods section and Supplementary Table 2 .
Efficacy and Safety Variables
This study's primary efficacy variable was to investigate the time to resolution of clinical symptoms, which was What You Need to Know Background As topical mesalamine standard treatment for proctitis is not always effective, we conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories.
Findings
Efficacy and safety of 4 mg budesonide suppository did not differ significantly from those of 1 g mesalamine suppository. Budesonide suppositories offer an alternative therapy to mesalamine for topical treatment of proctitis.
Implications for patient care 4 mg budesonide suppository is not yet available on the market and thus there are no current implications for patient care. A marketing authorization study is ongoing (EudraCT No.: 2016-001921-15).
calculated as the time period (days) from first treatment (baseline) to the first of 3 consecutive days with a score of 0 for rectal bleeding and stool frequency. Subgroup analyses, secondary efficacy variables, and safety variables are described in the Supplementary Methods section.
Statistical Analysis
The primary efficacy variable of time to resolution of clinical symptoms was evaluated using Kaplan-Meier analysis. The point estimates and corresponding 95% CIs for the median (50% percentile) time are presented by treatment. Treatment groups were compared pairwise using log-rank tests. The primary variable also was analyzed using a Cox proportional hazards regression model with treatment as factor; comparisons between treatments were presented as a hazard ratio with the associated 95% Wald CI and P value. Cox regression was performed for sensitivity analysis, including treatment and the subgroups as factors. All authors had access to the study data and reviewed and approved the final manuscript. Further details of the statistical analysis are shown in the Supplementary Methods section.
Results
A total of 337 patients were randomized and received at least 1 dose of study medication, and thus were evaluated in the safety and intention-to-treat population. Allocation of patients to the 4 different suppository treatment groups was as follows: 89 patients received 2 mg budesonide suppositories (2 mg BUS), 79 patients received 4 mg budesonide suppositories (4 mg BUS), 81 patients received 1 g mesalamine suppositories (1 g MES), and 88 patients received a combined treatment of 2 mg budesonide and 1 g mesalamine suppositories (2 mg BUS and 1 g MES). Subsequently, 59 patients were excluded from the per-protocol (PP) analysis set for major protocol violations. Hence, 278 patients were evaluable for PP analysis (Figure 1 ). In total, 27 (8.0%) patients stopped the trial prematurely.
We observed no relevant differences between treatment groups in demographics or anamnestic characteristics at baseline, although there were some minor imbalances that mainly concerned the proportion of patients with recurrent disease and the number of previous episodes (Table 1) .
Primary Efficacy Evaluation
Empiric time to resolution of clinical symptoms and the Kaplan-Meier estimators for median are shown in Table 2 . Patients in the 1 g MES treatment group resolved fastest from clinical symptoms, with slightly longer times in the 4 mg BUS and the combined 2 mg BUS and 1 g MES group. The longest time to clinical remission was observed under therapy with 2 mg BUS ( Figure 2B ). However, only the 1 g MES and combined groups showed significantly faster resolution of clinical symptoms than the 2 mg BUS group (2 mg BUS vs 1 g MES, P ¼ .041; 2 mg BUS vs 2 mg BUS and 1 g MES, P ¼ .031; log-rank test). In contrast, we found no significant treatment differences with the 4 mg BUS monotherapy in comparison with any of the other treatments or with combined treatment in comparison with the 1 g MES standard therapy.
Cox regression showed that the 2 mg BUS group experienced significantly longer time to resolution than the 1 g MES group (P ¼ .046; P value for hazard ratio [HR], 0.69; 95% CI, 0.47-0.99) or the combined 2 mg BUS and 1 g MES group (P ¼ .032; HR, 1.48; 95% CI, 1.03-2.12) (Figure 2A ). Our PP analysis findings were similar ( Figure 2A , Table 2 ).
Subgroup Analysis
Post hoc subgroup analysis on the primary efficacy end point among all subgroups showed statistically significant treatment differences only in the subgroups formed by the mUC-DAI at baseline. Consistent with milder disease, the subgroup with mUC-DAI 6 at baseline needed less time to resolution than patients with moderate to severe disease (mUC-DAI >6) ( Table 2 ). Pairwise comparison between treatment 
2.1 (0.6) UC-DAI subscore physician's rating of disease activity, mean (SD)
BUS, budesonide; MES, mesalamine; UC-DAI, Ulcerative Colitis Disease Activity Index; UC, ulcerative colitis. 
Secondary Efficacy End Points
The rates of patients showing improvement or remission based on mUC-DAI were analyzed as secondary end points. Deep, clinical, and endoscopic remission rates and mucosal healing were not significantly different statistically among the 4 mg BUS, 1 g MES, and the combined 2 mg BUS and 1 g MES treatment group (Table 3 , Supplementary Figure 1) . Treatment with 2 mg BUS, however, showed a significantly lower deep remission rate (difference, -18.03%; 95% CI, -32.64% to -3.43%) and clinical remission rate (difference, -17.23%; 95% CI, -31.83% to -2.62%) than 1 g MES. Regarding the endoscopic remission rate based on the mUC-DAI, only the combined 2 mg BUS and 1 g MES treatment was significantly better than the 2 mg BUS group (difference, 13.28%; 95% CI, 0.71%-25.85%), while the other treatment groups showed rates that were numerically but not significantly higher than the 2 mg BUS group. The endoscopic remission rate based on the Endoscopic Index was consistently much lower in the 2 mg BUS group compared with all other treatments (Table 3) , although it was achieved by approximately 79% of all patients of all treatment groups (266 of 337 patients). Histologic analysis of mucosal inflammation showed improvement in all treatment groups, but only a statistically significant different distribution of Histologic Index scores between the combined treatment and 2 mg BUS groups (P ¼ .007), whereas all other comparisons yielded a P value >.05.
The median time to first resolution of symptoms was similar among all treatment groups except the 2 mg BUS group, which needed significantly more time to resolve than the 1 g MES group (P ¼ .029, log-rank test) ( Table 3) .
Based on the Physician's Global Assessment at the final/withdrawal visit, the percentage of patients showing therapeutic success was significantly lower in the 2 mg BUS group than in the 1 g MES group (P ¼ .004) and in the combined 2 mg BUS and 1 g MES group (P ¼ .006), whereas the 4 mg BUS group's therapeutic success and all other comparisons showed no significant difference (Table 3) .
Most patients' self-reported signs and symptoms (stool consistency, occurrence, severity of abdominal pain/cramps, presence of rectal mucus, and tenesmus) normalized during the trial (data not shown). The 1 g MES group's related changes in most of these signs and symptoms at the end of treatment were greatest and less pronounced in each of the budesonide treatment groups, although there were no consistently verifiable, statistically significant differences between treatment groups (data not shown). Only the reduction in the number of bloody stools was statistically significantly lower in the 2 mg BUS (P ¼ .007) and 4 mg BUS groups (P ¼ .042) compared with the 1 g MES group.
Because intentional nonadherence is common in patients using rectal mesalamine (a factor detracting from therapeutic success 14 ), we also analyzed several factors influencing treatment adherence. Treatment acceptance was very good: most patients rated the morning (67%-79% of patients) and evening applications (69%-85% of patients) as being easy; we found no significant group differences in the self-reported ease of retaining and applying the suppositories. The suppositories generally were well accepted; only a total of 14 of 337 patients (4.2%) regarded the morning application (ie, budesonide or placebo) and 3 patients (0.9%) regarded the evening application (ie, mesalamine or placebo) as interfering considerably with their daily routine.
Safety
In total, 164 adverse events (AEs) occurred in 96 (28.5%) patients (Table 4 ). The wide majority of AEs were of mild severity; no severe AE was reported. Only 7 patients (2.1%) prematurely discontinued the trial because of an AE, 4 of them because of worsening UC, 1 because to AEs considered to be budesonide-related (preferred terms abdominal pain and pyrexia), and 2 patients because of other AEs showing no association with the trial medication. No serious AEs or deaths were reported.
The most important and common AE under budesonide treatment was a decreased blood-cortisol level, an expected drug reaction. Indicating dose-dependency, it was most frequent in the 4 mg BUS group, followed by the 2 mg BUS monotherapy (Table 4) . However, the mean changes in morning cortisol during treatment (2 mg BUS, -0.03 mg/dL; 4 mg BUS, -2.63 mg/dL; 1 g MES, 0.75 mg/dL; and 2 mg BUS/1 g MES, 1.01 mg/dL) were within the lower and upper limits (4.3-22.4 mg/dL) in all groups, and no clinically relevant effects on the hypothalamic-pituitary-adrenal axis were reported.
Discussion
In this randomized, double-blinded, clinical trial we compared the efficacy, acceptance, and safety of 2 budesonide suppositories (2 mg and 4 mg BUS) with the standard treatment (suppositories containing 1 g MES) as well as a combined budesonide-and-mesalamine suppository therapy (2 mg BUS and 1 g MES) in patients with mild to moderately active ulcerative proctitis.
The 4 mg BUS and combined 2 mg BUS and 1 g MES treatments were similarly very effective in patients with active ulcerative proctitis, showing no difference from the standard 1 g MES treatment with regard to the rapid resolution of clinical symptoms. Together with the standard 1 g MES therapy, both treatments resulted in a high rate of deep, clinical, and endoscopic remission, as well as mucosal healing. Moreover, these 3 groups' median times to first resolution of clinical symptoms (Table 3) were in line with published data on treatment with 1 g MES (5-7 days). 15 Considered together, these data provide evidence that the 4 mg BUS and combined 2 mg BUS and 1 g MES treatment regimens can be regarded as noninferior to 1 g MES therapy. On the other hand, because the 2 mg BUS monotherapy showed significantly lower efficacy than the other 3 treatment groups in almost all criteria, the data indicate that 4 mg BUS is superior to 2 mg BUS therapy.
This study analyzed the efficacy of budesonide suppositories in ulcerative proctitis. In contrast to mesalamine, the rectal administration of corticosteroids had been reported only in conjunction with enemas or foam formulations for both distal UC 7 and ulcerative proctitis alone. 7 It therefore is difficult to compare our results with those of studies using corticosteroid enemas and foam formulations. This is illustrated further by the fact that approximately 90% of liquid enemas and foam applications bypass the rectum. 16, 17 Despite these differences, earlier budesonide studies investigating enema or foam preparations in patients with distal UC and proctitis also detected evidence of dose-dependency in conjunction with rectal budesonide application, 18, 19 similar to our finding that 4 mg BUS was superior to 2 mg BUS. This also was reflected by 2 studies in patients with distal UC that reported 1 g mesalamine was superior to rectal application of the low 2 mg budesonide dose in high-volume enemas. 20, 21 An earlier study in patients with acute proctitis showed that the combined rectal administration of 
ADR, adverse drug reaction; BUS, budesonide; m, number of events; MES, mesalamine; N, number of patients; n, number of patients reporting adverse events; SAE, serious adverse event. enemas containing the corticosteroid beclomethasone dipropionate and mesalamine was significantly better than the single administration of each of those drugs. 22 However, we found no clinical advantage from suppositories in conjunction with combined budesonide and mesalamine treatment vs either mesalamine or budesonide monotherapy. To discover whether a combination of 4 mg BUS and 1 g MES is therapeutically more beneficial, further investigation is required.
Comparing patients with less-and more-intensive disease activity at baseline, we noted that times to resolution from clinical symptoms were obviously longer in patients with mUC-DAI >6 than in those with milder disease activity. However, this effect was apparent mainly in the 2 mg BUS, the 1 g MES, and the combined 2 mg BUS and 1 g MES groups. In contrast, the time to resolution in patients with less-and moreintensive disease activity was very similar in the 4 mg BUS group. Furthermore, treatment with 4 mg BUS showed the fastest time to resolution in patients with mUC-DAI >6 compared with the other treatment groups.
Whether this indicates that patients presenting more intensive disease activity benefit mainly from treatment with higher dosed budesonide, also in comparison with the standard mesalamine treatment, will have to be validated in future studies.
Despite their impressive efficacy and safety, rectal mesalamine therapies are underused 23 and nonadherence is a problem.
14 The use of liquid suspension enemas is a particular risk factor for nonadherence because of patients' inability to retain larger volumes in active disease. 6 Because patients obviously prefer suppositories to enemas, 24 we developed budesonide suppositories. They were very well accepted and only 4.2% of patients found that administration in the morning interfered considerably with their daily routine. Thus, for those who fail to respond or do not tolerate mesalamine therapy, these novel suppositories offer proctitis patients a more appealing alternative. The new suppositories enable much easier application than troublesome enema administration while delivering the drug more precisely to the rectum, something enemas are much less likely to achieve. 17 We found that all 4 treatments were well tolerated and similar to gold standard mesalamine therapy. Although relatively few patients in the budesonide groups presented decreased cortisol levels, we observed no clinical sequelae, and their cortisol levels remained within normal limits, thus verifying budesonide's excellent safety profile as reported in numerous studies in conjunction with oral and rectal preparations with AE rates similar to those of placebo. 19, [25] [26] [27] [28] In conclusion, our study shows similar efficacy and safety as well as excellent acceptance of novel budesonide suppositories and the gold standard 1 g MES suppositories in patients with active ulcerative proctitis. Our findings show a novel treatment alternative for patients intolerant of mesalamine or nonadherent to rectal foam or enemas. Budesonide suppositories showed dose dependency, with 4 mg BUS being superior to 2 mg BUS. Although the combination of 2 mg BUS with 1 g MES showed no therapeutic advantages over monotherapy, the combination of MES with 4 mg BUS deserves further investigation in future trials. It remains unclear whether such a combination or even single 4 mg BUS administration is an option for patients with proctitis refractory to MES.
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Supplementary Methods
Exclusion Criteria
Patients with Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, diverticular-associated colitis, microscopic colitis, proctitis of a different origin, prior bowel resection leading to diarrhea and/or pouch formation, toxic megacolon, presence of symptomatic organic disease of the gastrointestinal tract (with the exception of nonbleeding hemorrhoids or hiatal hernia), present or past colorectal cancer, or serious other secondary disease(s) were excluded. The use of steroids within 1 month or use of immunosuppressants or tumor necrosis factor-a antibodies within 3 months before inclusion also was prohibited. Patients who had undergone regular treatment with >0.5 g rectal or >2 g oral mesalamine within the past 4 weeks, or corresponding doses of rectal or oral sulfasalazine, as well as patients with transaminase or alkaline phosphatase levels 2 times the upper limit of normal or abnormal renal function (cystatin C level > upper limit of normal) were excluded as well. The regular intake of nonsteroidal antiinflammatory drugs within the 2 weeks before the baseline visit was a further exclusion criterion. Female patients had to present a negative pregnancy test at baseline.
Study Medications
The test product was 2 budesonide suppositories with either 2 mg or 4 mg budesonide. The mesalamine suppository used as a reference or for the combination treatment was a 1 g mesalamine suppository (Salofalk 1 g suppository; Dr. Falk Pharma, Freiburg, Germany). During the 8-week trial, budesonide suppositories and budesonide placebo were administered once daily in the morning, 1 g mesalamine suppositories or placebo were administered once daily at bedtime.
Procedures
At baseline, all patients underwent a physical examination and their demographics and medical history were recorded. Vital signs and routine laboratory values were assessed at each visit. The timing and sequence of all assessments and procedures are described in Supplementary Table 2. A total colonoscopy was performed in patients with a newly established UC diagnosis (at baseline), and a rectosigmoidoscopy was performed in patients with known UC (reaching the end of bowel inflammation). A rectosigmoidoscopy sufficed at the final visit. The diagnosis of acute ulcerative proctitis was assessed both endoscopically and histologically. The upper limit of disease extent was visualized by rectosigmoidoscopy/colonoscopy performed during the week before baseline. Moreover, biopsy specimens were taken at baseline and the final visit and analyzed by a central pathologist. If the histology result at baseline did not confirm the UC diagnosis, the patient had to be withdrawn. The mUC-DAI [1] [2] [3] was assessed at baseline, at the 3 interim visits every 2 weeks, and at the final visit in week 8. Furthermore, efficacy was assessed by applying the following scores/scales: the Endoscopic Index according to Rachmilewitz 4 assessed by the same investigator at baseline and the final visit, the Histologic Index (HI) according to Riley et al 5 assessed by a central pathologist at baseline and the final visit (no signs of ulcerative colitis, 0 points; remission, 1 point; mild activity, 2 points; moderate activity, 3 points; and severe activity, 4 points), Physicians' Global Assessment of efficacy, 6 the investigator's and patient's assessment of efficacy/tolerability (classified by investigator and patient independently at the final/withdrawal visit as very good, good, satisfactory, or poor), and the patient's acceptance of the study drug assessed at the final examination or upon the patient's withdrawal. Concomitant medications and AEs were documented at every visit. The patients had to return unused study medication at every visit. The trial investigators documented treatment adherence by counting the unused study medication at the visits and by checking the patient's diary.
Post Hoc Subgroup Analyses on the Primary Efficacy Variable
For post hoc subgroup analyses on the primary efficacy variable (time to resolution of clinical symptoms), several subgroups were formed and analyzed by the following criteria: sex (male/female), mUC-DAI at baseline visit (6, >6), smoking history (current/former/ never/unknown), time since first symptoms of ulcerative proctitis (5 y, >5 y), extraintestinal disease symptoms at baseline visit (absence, presence), and country (Germany/Russia/Ukraine).
Secondary Efficacy Variables
Secondary efficacy end points included rate of deep remission (defined by mUC-DAI 1, with a score of 0 for rectal bleeding and stool frequency; no mucosal friability, ie, subscore for mucosal appearance 1; and at least a 1-point reduction in subscore for mucosal appearance) at the final/withdrawal visit compared with baseline; the rate of patients with clinical remission as defined by mUC-DAI subscores rectal bleeding and stool frequency of 0 at the final/withdrawal visit; rate of patients with endoscopic remission as defined by mUC-DAI subscores mucosal appearance <2, and at least a 1-point reduction at final/withdrawal visit compared with baseline; the rate of patients with mucosal healing, defined by mUC-DAI subscore mucosal appearance <2 at the final/withdrawal visit; rate of improvement (defined as mUC-DAI reduction 3 from baseline to the final/ withdrawal visit); rate of patients with endoscopic remission based on Endoscopic Index (Endoscopic Index <4 at final visit, last observation carried forward); rate of patients with histologic improvement (decrease of Histologic Index 1 at final/withdrawal visit from baseline); change in clinical symptoms from baseline to final/ withdrawal visit; time to first resolution of symptoms (3 stools/d, all without blood); patients global assessment (at least good); therapeutic success (Physician Global Assessment assessed as complete relief or marked improvement) and therapeutic benefit (Physician Global Assessment at least assessed as slight improvement) at final visit; and acceptance of the study drug.
Safety Variables
The frequency of AEs, clinically relevant changes in any laboratory parameters, and vital signs were assessed for the safety population.
Patient Diaries
The patients recorded the number of stools, number of stools with rectal bleeding (mUC-DAI subscore 1 and 2), number of stools with blood in or on stool, number of liquid/soft/solid stools, occurrence and severity of abdominal pain and cramps, presence of rectal mucus and tenesmus, occurrence of fever and regular use of study medications, as well as intake of additional drugs on a daily basis in a diary.
Statistical Analysis
Efficacy analyses were performed according to the intention-to-treat principle as well as on patients without major protocol deviations (PP population). The safety analysis set included all patients treated who had at least 1 follow-up value for safety variables to be analyzed.
The rate (number and percentage) of patients with improvement or remission based on mUC-DAI at the final/withdrawal examination were calculated for the 4 treatment groups and compared exploratively (pairwise comparison) using 95% CIs (normal approximation) for the difference of proportions.
The frequency of patients in endoscopic remission (Endoscopic Index <4)/with endoscopic improvement (decrease of Endoscopic Index by at least 1 point), and change in physician's rating of disease activity was analyzed using descriptive statistics and compared between the 4 groups.
The time to resolution of first symptoms was evaluated with Kaplan-Meier analysis and pairwise log-rank tests.
Where appropriate, missing values at the final or withdrawal visit were imputed by the last measurement obtained during treatment (last observation carried forward). spontaneous bleeding Physician's rating of disease activity Normal Mild Moderate Severe
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